炎症性肠病是病因不明的慢性疾病,在几个国家显示发病率和患病率不断上升,包括意大利。虽然克罗恩病和溃疡性结肠炎的病因尚不清楚,由于目前有关其发病机制的知识,已经制定了有效的治疗策略。关于炎性肠病的可用药物治疗的功效和安全性,有几个指南可用。然而,国家指南提供了适应当地可行性的额外信息,与使用相同药物有关的费用和法律问题。这些观察结果促使意大利炎症性肠病研究小组(IG-IBD)建立了关于克罗恩病和溃疡性结肠炎目前可用治疗方法安全性的意大利指南。这些指南讨论了氨基水杨酸盐的使用,全身性和低生物利用度的皮质类固醇,抗生素(甲硝唑,环丙沙星,利福昔明),硫嘌呤,甲氨蝶呤,环孢菌素A,TNFα拮抗剂,维多珠单抗,和组合疗法。这些指南基于基于循证医学的最新知识以及国家工作组的临床经验。
Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a growing incidence and prevalence in several countries, including Italy. Although the etiology of Crohn\'s disease and ulcerative colitis is unknown, due to the current knowledge regarding their pathogenesis, effective treatment strategies have been developed. Several
guidelines are available regarding the efficacy and safety of available drug treatments for inflammatory bowel diseases. Nevertheless, national
guidelines provide additional information adapted to local feasibility, costs and legal issues related to the use of the same drugs. These observations prompted the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) to establish Italian
guidelines on the safety of currently available treatments for Crohn\'s disease and ulcerative colitis. These
guidelines discuss the use of aminosalicylates, systemic and low bioavailability corticosteroids, antibiotics (metronidazole, ciprofloxacin, rifaximin), thiopurines, methotrexate, cyclosporine A, TNFα antagonists, vedolizumab, and combination therapies. These
guidelines are based on current knowledge derived from evidence-based medicine coupled with clinical experience of a national working group.